• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Utility of Human Plasma Derived Butyrylcholinesterase (huBuChE): A Therapeutic Measure in the Absence of Pre-Treatment or Conventional Post-Poisining Therapies Against Nerve Agent
【24h】

Utility of Human Plasma Derived Butyrylcholinesterase (huBuChE): A Therapeutic Measure in the Absence of Pre-Treatment or Conventional Post-Poisining Therapies Against Nerve Agent

机译：人血浆衍生的丁酰胆碱酯酶（huBuChE）的实用性：在没有预处理或常规后期治疗神经毒剂的治疗措施

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of this study was to demonstrate, in guinea-pigs in vivo, the utility of huBuChE as a therapy against percutaneous (p.c.) nerve agent poisoning, following which there is a slower absorption of agent than by the inhalation route and consequently a longer window of opportunity for therapeutic intervention. The first task was to determine the p.c. toxicity of VR in Dunkin-Hartley guinea-pigs. The 24h LD50 was 0.45mg/kg (0.36 0.54 95% CI) and the 48-h LD50 was 0.38 mg/kg (0.31-0.45 95% CI). The second task was to investigate the efficacy of huBuChE therapy following p.c. VR. Following VR (0.6mg/kg, p.c.) guinea-pigs were monitored for the onset of observable signs of systemic cholinergic poisoning. At this time, either huBuChE (24.2 mg/kg) or saline was administered by either the intramuscular or intravenous route. The onset of observable signs of cholinergic therapy used as the trigger for therapy dosing was between 5h and 9h following VR challenge. Preliminary results indicate that therapy using huBuChE via the i.v. route was more effective than therapy via the i.m. route.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号